NYSE:DGXHealthcare
Quest Diagnostics (DGX) Is Up 8.5% After Strong 2026 Guidance And New Myeloma Test Launch - Has The Bull Case Changed?
In February 2026, Quest Diagnostics reported Q4 and full-year 2025 results with higher sales and earnings, issued 2026 guidance calling for US$11.70–US$11.82 billion in revenue and US$9.45–US$9.65 in diluted EPS, raised its quarterly dividend to US$0.86 per share, expanded its share repurchase authorization to US$10.50 billion, and signaled plans for additional hospital and independent lab acquisitions.
The company also launched a new blood-based measurable residual disease test for multiple...